<DOC>
	<DOCNO>NCT00064181</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy irinotecan , capecitabine , leucovorin , fluorouracil use different way stop tumor cell divide stop grow die . Celecoxib may stop growth colorectal cancer stop blood flow tumor . It yet know combination chemotherapy regimen without celecoxib effective treat metastatic colorectal cancer . PURPOSE : This randomized phase III trial study two combination chemotherapy regimens celecoxib see well work compare two combination chemotherapy regimens alone treating patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Celecoxib Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free survival patient metastatic colorectal cancer treat capecitabine irinotecan v fluorouracil , leucovorin calcium , irinotecan v without celecoxib . - Compare safety regimens patient . - Compare response rate patient treat regimen . - Compare time treatment failure overall survival patient treat regimen . OUTLINE : This randomize , double-blind* , multicenter study . Patients stratify accord participate center , prior adjuvant therapy ( yes v ) , risk group ( poor v intermediate vs good ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive irinotecan IV 30-90 minute day 1 22 ; oral capecitabine twice daily day 1-15 22-36 ; oral celecoxib twice daily day 1-42 . - Arm II : Patients receive irinotecan capecitabine arm I oral placebo twice daily day 1-42 . - Arm III : Patients receive irinotecan IV 30-90 minute day 1 , 15 , 29 ; leucovorin calcium ( CF ) IV 2 hour fluorouracil ( 5-FU ) IV 22 hour day 1 , 2 , 15 , 16 , 29 , 30 ; oral celecoxib twice daily day 1-42 . - Arm IV : Patients receive irinotecan , CF , 5-FU arm III oral placebo twice daily day 1-42 . In arm , treatment repeat every 6 week 6 course absence disease progression unacceptable toxicity . If chemotherapy discontinue due toxicity , patient may continue celecoxib placebo disease progression , unacceptable toxicity , start new cytotoxic regimen . NOTE : *The double-blind treatment applies celecoxib placebo randomization Patients follow every 2 month . PROJECTED ACCRUAL : A total 692 patient ( 173 per treatment arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Metastatic disease Measurable disease Patients receive prior radiotherapy must measurable evaluable disease outside radiotherapy field No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( 5 time ULN presence liver metastasis ) Renal Creatinine clearance least 51 mL/min No severe renal impairment Cardiovascular No severe cardiac disease No uncontrolled angina pectoris No myocardial infarction within past 6 month Other Not pregnant nursing Fertile patient must use effective contraception 6 month study participation No active Crohn 's disease No malignancy except adequately treat carcinoma situ cervix nonmelanoma skin cancer No uncontrolled severe medical condition No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent active passive immunotherapy colon cancer Chemotherapy No prior chemotherapy metastatic disease Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other At least 6 month since prior adjuvant therapy More 4 week since prior investigational drug No concurrent sorivudine chemically related analogue ( e.g. , brivudine ) No concurrent investigational drug No concurrent cytotoxic agents No concurrent prophylactic fluconazole No concurrent plan cyclooxygenase2 ( COX2 ) inhibitor nonsteroidal antiinflammatory drug No concurrent chronic use fulldose aspirin ( 325 mg/day great ) Concurrent lowdose ( cardioprotective ) aspirin prophylaxis ( 325 mg every day OR 162.5 mg per day ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>